// App-Quantinova.ai

8511 : Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Researchers

Presenter

  • David R. Spigel

Principal Investigators

  • Jhanelle Elaine Gray

  • David Vicente

  • David Planchard

  • Luis G. Paz-Ares

  • Johan F. Vansteenkiste

  • Marina Chiara Garassino

  • Rina Hui

  • Xavier Quantin

  • Andreas Rimner

  • Yi-Long Wu

  • Mustafa Ozguroglu

  • Ki Hyeong Lee

  • Terufumi Kato

  • Maike de Wit

  • Euan Macpherson

  • Michael Newton

  • Piruntha Thiyagarajah

  • Scott Joseph Antonia

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, The Christie NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom

  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Hospital Universitario Virgen Macarena, Seville, Spain

  • Department of Medical Oncology - Institut Gustave Roussy, Villejuif, France

  • CiberOnc, Universidad Complutense and CNIO, Hospital Universitario 12 de Octubre, Madrid, Spain

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Montpellier Cancer Institute (ICM)and Montpellier Cancer Research Institute (IRCM), INSERM U1194, Montpellier, France

  • Memorial Sloan Kettering Cancer Center, New York, NY, Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea

  • Kanagawa Cancer Center, Yokohama, Japan

  • Vivantes Klinikum Berlin, Berlin, Germany

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

  • Spain

  • France

  • Belgium

  • Italy

  • Australia

  • China

  • Turkey

  • Japan

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02125461

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved